Table 2. Chemotherapy regimens and treatment duration in different lines of therapy.
| Immunocompetent (n = 29) | Overall (n = 34) | |||
|---|---|---|---|---|
| n | % | n | % | |
| First-line regimens Liposomal doxorubicin Carboplatin + etoposide Carboplatin + paclitaxel Cisplatin + etoposide Cisplatin + paclitaxel Cyclophosphamide + methotrexate + 5-fluorouracil Doxorubicin Etoposide Paclitaxel |
8 1 1 4 2 1 1 1 10 |
27.6 3.5 3.5 13.8 6.9 3.5 3.5 3.5 34.5 |
10 1 1 6 2 1 1 1 11 |
29.4 2.9 2.9 17.7 5.9 2.9 2.9 2.9 32.4 |
| Second-line regimens Carboplatin + etoposide Carboplatin + paclitaxel Cisplatin + etoposide Cisplatin + paclitaxel Cyclophosphamide + doxorubicin + vincristine Doxorubicin Liposomal doxorubicin Paclitaxel |
8 1 3 1 2 3 7 4 |
27.6 3.5 10.3 3.5 6.9 10.3 24.1 13.8 |
9 2 3 1 2 3 10 4 |
26.5 5.9 8.8 2.9 5.9 8.8 29.4 11.8 |
| Third-line regimens Cisplatin + etoposide Doxorubicin Etoposide Paclitaxel Temozolomide |
1 1 1 1 1 |
20.0 20.0 20.0 20.0 20.0 |
1 1 1 1 1 |
20.0 20.0 20.0 20.0 20.0 |
| Median | Range | Median | Range | |
| Duration of treatment, months First-line Second-line Third-line |
4.5 2.6 2.5 |
1.8–6.0 1.5–5.9 1.6–3.2 |
4.6 2.6 2.5 |
1.7–6.0 1.4–5.9 1.6–3.2 |